secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000950170-25-026070
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics reports Q4 net loss of $90.4M; cash $850.7M, clinical milestones reaffirmed
--------------------------------------------------------------------------------

- Net loss per share $1.09 in Q4 2024 vs net income of $1.77 in Q4 2023; full-year net loss $4.58 per share vs $1.72 in 2023.
- Cash, equivalents and marketable securities $850.7M at Dec 31, 2024, expected to fund operations into 2027.
- Adult enrollment target achieved in BEACON trial of BEAM-101; updated data and 30 patients dosed expected by mid-2025.
- Initial data from BEAM-302 Phase 1/2 in alpha-1 antitrypsin deficiency expected in H1 2025; BEAM-301 dosing to start early 2025.
- Appointed Sravan Emany as CFO; Chirfi Guindo to board; IND-enabling studies for ESCAPE conditioning ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017025026070/0000950170-25-026070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017025026070/beam-20250225.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-026070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer